Spots Global Cancer Trial Database for The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients

Study Description

Brief Summary: Testing the effect of providing an antidepressant and anxiety-type escitalopram for patients with glioblastoma on patient's quality of life including the effect of treatment on mood and cognition during treatment.Two subgroups will fill questionnaires : * Questionnaire mini mental state exam (mmse) which is the maximum score of 30. A score of below 24 indicates a flaw in the level of dementia * Questionnaire depression / mood PHQ9P(Pa t i e n t H e a l t h Qu e s t i o n n a i r e - 9) * The M. D. Anderson Symptom Inventory (MDASI) * Evaluation of the hospital situation awareness (clinical assessment and questionnaire) * Cognitive assessment which will be carried out by the Department neuropsychological and include: * Executive function (Stroop) * Abstract Reasoning (similarities) * -Auditory and Spatial Attention (Digit span, Spatial span) visual memory and remembering Literature * Memory function - visual and auditory (ROCF, RAVLT) * Language function: Naming and verbal fluency * Mindstreems Neurotrax

Detailed Description: This study is planned as prospective randomized, controlled, double-blind study. Patients will undergo resection or biopsy of glioblastoma (newly diagnosed glioblastoma), will randomization ratio of 1: 1 by the pharmacist (by age,Karnofsky score, extent of tumor resection), for two research groups: Group number 1 will include 50 patients, who will receive Escitalopram or Placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months. . The dose study is fixed and is not aimed at symptomatic treatment of anti-depressant (such as major depression).

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial